Telo Genomics Corp. reported earnings results for the second quarter and six months ended December 31, 2022. For the second quarter, the company reported net loss was CAD 0.63921 million compared to CAD 0.463297 million a year ago. Basic loss per share from continuing operations was CAD 0.01 compared to CAD 0.01 a year ago. Diluted loss per share from continuing operations was CAD 0.01 compared to CAD 0.01 a year ago.
For the six months, net loss was CAD 1.26 million compared to CAD 0.94224 million a year ago. Basic loss per share from continuing operations was CAD 0.02 compared to CAD 0.02 a year ago.